E138A in HIV-1 reverse transcriptase is more common in subtype C than B: Implications for rilpivirine use in resource-limited settings

Ítems similars

• Competitive Fitness Assays Indicate that the E138A Substitution in HIV-1 Reverse Transcriptase Decreases In Vitro Susceptibility to Emtricitabine
  per: Sluis-Cremer, Nicolas, et al.
  Publicat: (2014)
• Frequent Emergence of N348I in HIV-1 Subtype C Reverse Transcriptase with Failure of Initial Therapy Reduces Susceptibility to Reverse-Transcriptase Inhibitors
  per: Brehm, Jessica H., et al.
  Publicat: (2012)
• In Vitro Cross-Resistance Profiles of Rilpivirine, Dapivirine, and MIV-150, Nonnucleoside Reverse Transcriptase Inhibitor Microbicides in Clinical Development for the Prevention of HIV-1 Infection
  per: Giacobbi, Nicholas S., et al.
  Publicat: (2017)
• Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase
  per: Barnard, John P., et al.
  Publicat: (2019)
• Future of nonnucleoside reverse transcriptase inhibitors
  per: Sluis-Cremer, Nicolas
  Publicat: (2018)